Piramal Pharma Ltd management interview: Piramal Pharma Gains 18% Q2 Revenue Jump of 28% | CNBC TV18
CNBC-TV18, 2026-10-28. Video: https://www.youtube.com/watch?v=84Xg_Dij6Tg
- Revenue guidance: Piramal Pharma raised full-year revenue growth guidance to 19 to 20%, aiming to balance growth between H1 and H2; H1 revenue growth was around 23%.
- Profitability outlook: Management expects significant improvement in earnings and PAT as revenue grows, because much of the business has fixed costs.
- CDMO pipeline: The company onboarded 22 new customers, mostly US biotechs, all in CDMO. Its Phase 3 pipeline has increased to 28 molecules, which could reach commercial manufacturing within the next 1, 2, and 3 years if they pass clinical readouts.
- Segment growth and debt: In the first half, CDMO grew 23%, complex hospital generics 24%, and ICH consumer business 14%. Net debt-to-EBITDA has declined over the year as EBITDA improved, and management expects it to reach a manageable number.